相似文献
1
Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?
Cardiovasc Diabetol. 2017 Jul 19;16(1):91. doi: 10.1186/s12933-017-0573-z.
2
The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):e174-e177. doi: 10.1161/ATVBAHA.117.310097. Epub 2017 Sep 28.
3
Why the CANTOS Is a Game Changer in Cardiovascular Medicine.
J Cardiovasc Pharmacol. 2017 Dec;70(6):353-355. doi: 10.1097/FJC.0000000000000546.
4
CANTOS - is selective targeting of inflammation in atherosclerosis enough?
J R Coll Physicians Edinb. 2018 Sep;48(3):246-247. doi: 10.4997/JRCPE.2018.310.
5
Brodalumab versus ustekinumab in psoriasis.
Dermatol Ther. 2016 Sep;29(5):298. doi: 10.1111/dth.12323. Epub 2015 Dec 2.
6
CANTOS: One year on: When the findings of the CANTOS trial were unveiled at ESC Congress 2017 in Barcelona, there was a sense of hope that a new era in preventive cardiology was set to begin. One year on, CANTOS Principle Investigator and study author Paul M. Ridker discusses whether that optimism is being realized.
Eur Heart J. 2018 Dec 1;39(45):3989-3990. doi: 10.1093/eurheartj/ehy702.
7
CANTOS: A Gigantic Proof-of-Concept Trial.
Circ Res. 2017 Dec 8;121(12):1320-1322. doi: 10.1161/CIRCRESAHA.117.312200.
8
Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease.
Clin Pharmacol Ther. 2015 Aug;98(2):121-3. doi: 10.1002/cpt.105. Epub 2015 Jun 26.
9
Case report of Klinefelter's syndrome with severe diabetes, dyslipidemia, and stroke: The effect of pioglitazone and other anti-inflammatory agents on interleukin-6 and -8, tumor necrosis factor-alpha, and C-reactive protein.
Diabetes Care. 2006 Aug;29(8):1981. doi: 10.2337/dc06-0651.
10
[Biologic therapy for inflammatory bowel diseases].
Rev Gastroenterol Mex. 2006 Aug;71 Suppl 1:91-4.
引用本文的文献
1
Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology.
Diabetes Metab Syndr Obes. 2022 Mar 3;15:695-711. doi: 10.2147/DMSO.S346648. eCollection 2022.
2
Interleukin-1β enhances cell adhesion in human endothelial cells via microRNA-1914-5p suppression.
Biochem Biophys Rep. 2021 Jun 12;27:101046. doi: 10.1016/j.bbrep.2021.101046. eCollection 2021 Sep.
3
Temporal relationship between inflammation and insulin resistance and their joint effect on hyperglycemia: the Bogalusa Heart Study.
Cardiovasc Diabetol. 2019 Aug 23;18(1):109. doi: 10.1186/s12933-019-0913-2.
4
Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis.
Cardiovasc Diabetol. 2018 Jun 12;17(1):87. doi: 10.1186/s12933-018-0733-9.
5
Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
Cardiovasc Diabetol. 2018 May 30;17(1):75. doi: 10.1186/s12933-018-0723-y.
6
Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sci Rep. 2018 Mar 27;8(1):5276. doi: 10.1038/s41598-018-23420-4.
7
Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.
Front Physiol. 2018 Feb 20;9:114. doi: 10.3389/fphys.2018.00114. eCollection 2018.
本文引用的文献
1
The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Cardiovasc Diabetol. 2017 May 22;16(1):69. doi: 10.1186/s12933-017-0551-5.
2
Nutritional anti-inflammatories in the treatment and prevention of type 2 diabetes mellitus and the metabolic syndrome.
Diabetes Res Clin Pract. 2017 May;127:238-253. doi: 10.1016/j.diabres.2017.02.019. Epub 2017 Feb 20.
3
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Cardiovasc Diabetol. 2016 Dec 3;15(1):162. doi: 10.1186/s12933-016-0480-8.
4
Impact of visceral fat on gene expression profile in peripheral blood cells in obese Japanese subjects.
Cardiovasc Diabetol. 2016 Nov 29;15(1):159. doi: 10.1186/s12933-016-0479-1.
5
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Cardiovasc Diabetol. 2016 Nov 11;15(1):157. doi: 10.1186/s12933-016-0473-7.
6
Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Cardiovasc Diabetol. 2016 Aug 26;15(1):121. doi: 10.1186/s12933-016-0437-y.
7
TNF-α induces vascular insulin resistance via positive modulation of PTEN and decreased Akt/eNOS/NO signaling in high fat diet-fed mice.
Cardiovasc Diabetol. 2016 Aug 25;15(1):119. doi: 10.1186/s12933-016-0443-0.
8
Common dysregulated pathways in obese adipose tissue and atherosclerosis.
Cardiovasc Diabetol. 2016 Aug 26;15(1):120. doi: 10.1186/s12933-016-0441-2.
9
Glucose intolerance after chronic stress is related with downregulated PPAR-γ in adipose tissue.
Cardiovasc Diabetol. 2016 Aug 19;15(1):114. doi: 10.1186/s12933-016-0433-2.
10
Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women.
Int J Med Sci. 2016 Jun 25;13(7):490-9. doi: 10.7150/ijms.14110. eCollection 2016.
Zotero 插件